Comparative Pharmacology
Head-to-head clinical analysis: HYDROPRES 50 versus NAQUIVAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROPRES 50 versus NAQUIVAL.
HYDROPRES 50 vs NAQUIVAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride cotransporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reserpine is a rauwolfia alkaloid that depletes catecholamines and serotonin from central and peripheral nerve endings, reducing sympathetic outflow and lowering blood pressure. The combination provides additive antihypertensive effect.
NAQUIVAL (trichlormethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, reducing electrolyte reabsorption and increasing urine output, thereby lowering blood pressure and reducing edema.
HYDROPRES 50 is a fixed-dose combination of hydrochlorothiazide 50 mg and reserpine 0.125 mg. Usual adult dose: one tablet orally once daily.
Adults: 0.1 mg/kg IV bolus, then 0.1 mg/kg/hour continuous IV infusion, titrated to clinical response. Maximum 0.5 mg/kg/hour.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hr (terminal); Reserpine: 50-100 hr (terminal, biphasic). Clinical: HCTZ half-life prolonged in renal impairment; reserpine accumulates with repetitive dosing.
Terminal elimination half-life: 14-16 hours (healthy adults). Extended to 26-35 hours in heart failure or hepatic cirrhosis due to reduced clearance.
Hydrochlorothiazide: 95% renal (65% unchanged); Reserpine: 30% renal, 60% fecal
Renal: 50-60% as unchanged drug; fecal: <10% (biliary); remainder as metabolites (80% renal, 10% fecal).
Category C
Category C
Thiazide Diuretic Combination
Thiazide Diuretic Combination